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Purpose: To describe the course and outcome of treatment of advanced Acanthamoeba 
sclerokeratitis with intravenous pentamidine.
Methods: A case of advanced Acanthamoeba sclerokeratitis was resistant to conventional 
therapy and was treated with intravenous pentamidine. The eye was later removed due to inca-
pacitating pain.
Results: The eye showed Acanthamoeba organisms within the cornea and evidence of acute 
and chronic inflammation throughout the remainder of the eye. The patient has survived without 
orbital recurrence for 2 years.
Conclusions: This case demonstrates late inflammation with active Acanthameoba keratitis 
following systemic pentamidine therapy.
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Introduction
Acanthamoebal sclerokeratitis is an uncommon and severe complication of advanced 
Acanthamoeba keratitis (AK).1–3 Despite intensive medical and surgical treatment, 
enucleation may be required to manage this disease. Pentamidine has shown 
effectiveness against Acanthamoeba with synergistic effects when used in combination 
with polyhexamethylene biguanide (PHMB).4–10 In vitro testing may not always be 
associated with in vivo effectiveness.11
Case report
A 59-year-old female presented for a second opinion with previously diagnosed AK 
of her right eye. She was a daily soft contact lens wearer for many years. The contact 
lens type and solution were unknown, but she did wash her contact lens case out with 
tap water on a regular basis. She first noted pain and decreased vision in the right eye 
approximately 2 years earlier and saw an ophthalmologist. A ring stromal opacity 
was seen and she was treated for herpetic keratitis. Several months later she was 
diagnosed with acute retinal necrosis and was hospitalized and treated with foscarnet. 
The patient underwent penetrating keratoplasty in the right eye 9 months after initial 
treatment for presumed corneal opacity secondary to herpes simplex keratitis. The 
pathological examination of the corneal button demonstrated Acanthamoeba cysts. 
The eye was treated with topical antiamoebal therapy and systemic fluconazole. 
Treatment was continued for 1 year when the patient presented at our institution for 
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Her ocular medications on presentation were: topical 
PHMB every 2–3 hours, topical propamidine (Brolene®) 
three times per day, topical moxifloxacin (Vigamox®) three 
times per day, prednisolone actetate 1% every 2–3 hours, and 
dorzolamide-timolol (Cosopt®) three times per day. She was 
also on oral famcyclovir and fluconazole. She had apparently 
had multiple (10–12) subtenons injections of triancinolone 
(Kenalog®) over the past year.
On examination, visual acuity in the right eye was hand 
motion at 1 foot with light projection in all quadrants. Visual 
acuity in the left eye was 20/20 with correction. The cornea 
showed a penetrating graft with moderate stromal edema 
and epithelial bedewing. Grade one fine keratic precipitates 
were also present (Figures 1A and 1B). The sclera showed 
moderate injection, and there was a white plaque consistent 
with triancinolone present beneath Tenons capsule superiorly. 
Intraocular pressure was 12 mm Hg. The anterior chamber 
appeared quiet, and the iris was dilated and unreactive. 
A mature cataract was present. The retina of the right eye 
could not be visualized, but ultrasound B scan showed a 
clear vitreous cavity and intact retina. Confocal microscopy 
(Confoscan 3 – Nidek) of the corneal graft showed cystic 
structures consistent with Acanthamoeba throughout the 
depth of the cornea (Figure 2). The left eye examination 
was normal.
Famcyclovir was discontinued, and topical propamidine, 
clotrimazole 1% and chlorhexidine 0.02% were added every 
hour for the first week and then decreased to every 2 hours. 
Prednisolone actetate 1% was reduced to four times per day, 
and dorzolamide-timolol was reduced to twice per day. The 
moxifloxacin was continued.
One month after presentation the eye had shown no 
improvement. The patient was admitted to the hospital under 
the infectious disease service for a course of intravenous 
pentamidine. She was given intravenous pentamidine 200 mg 
every 24 hours for 20 consecutive days. The treatment was 
associated with nausea, but no episodes of hypotension or 
hypoglycemia occurred. Her topical antiamebial therapy 
was continued for 20 days. Eleven days into this course 
of treatment a combined penetrating keratoplasty, cataract 
removal with lens implant was performed. Pathologic 
examination of the cornea demonstrated multiple stromal 
acanthamoebal cysts (Figure 3). Retinal examination 
following surgery demonstrated diffuse chorioretinal scarring 
but no evidence of active inflammation. Orbital and brain 
Figure  2  Confocal  microscopy  demonstrating  cystic  structures  in  the  corneal 
stroma consistent with Acanthamoeba.
A
Figure 1 A) Affected eye at presentation with mild corneal edema and fine keratic 
precipitates. B) scleritis with scleral thinning and subtenon’s triamcinolone.
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computed tomography (CT) scan and magnetic resonance 
imaging (MRI) were performed during the hospitalization 
and did not demonstrate any orbital or intracranial extension. 
She did have evidence of bilateral paranasal sinus disease. 
The patient was discharged in good condition. One month 
following her eye surgery her cornea was found to be clear 
with a quiet anterior chamber and posterior chamber lens 
implant. Scleral inflammation had improved significantly. Her 
pain had also improved. Vision was count fingers at 1 foot 
and was limited by the chorioretinal scarring. Her topical 
medications were moxifloxacin, Neosporin®, PHMB, clotri-
mazole 1%, chlorhexidine 0.02%, and prednisolone actetate 
1%, all four times per day. She was also using atropine 1% 
and dorzolamide-timolol, each twice per day. She was using 
fluconazole orally.
The eye remained stable, and the patient continued her 
medications for 6 months when she presented with a 1 week 
history of pain. Examination noted a 2 mm cream-colored 
loculated mass in the superior anterior chamber (Figure 4). The 
mass was removed in the operating room and sent for bacterial, 
fungal, and acanthamoebal cultures. Calcaflor white stain was 
negative for organisms. Cultures grew one colony of coagulase 
negative staphylococcus, which was felt to be a contaminant. 
Vancomycin 1.0 mg was given intravitreally 2 days following 
surgery. The intraocular inflammation progressed over the next 
3 weeks and a trans pars plana vitrectomy was performed with 
intravitreal injection of vancomycin 1.0 mg and ceftazidine 
2.25 mg. At the time of this surgery the patient was again 
admitted and given a 4-day course of intravenous pentamidine 
200 mg per day. Bacterial, fungal, and acanthamoebal cultures 
from the vitreous washings were all negative.
The postoperative medications were PHMB, clotrimazole, 
chlorhexidine, Neosporin, propamidine, and prednisolone 
actetate, all every hour for the first week and then tapered to 
4 times per day. She was also on atropine 1% twice per day 
and oral ketaconazole. The eye remained inflamed and painful 
with vision of light perception but no accurate projection. 
Confocal microscopy demonstrated structures within the 
corneal stroma consistent with Acanthamoeba (Figure 5). 
Ultrasound demonstrated a funnel retinal detachment. The 
patient refused any additional treatment other than the topi-
cal medications. The eye was enucleated 3 months later due 
to severe pain. The patient has done well since enucleation 
with no evidence of recurrent disease. The pathology of the 
enucleated globe demonstrated acanthamoebal cysts within 
the cornea (Figure 6) and evidence of acute and chronic 
inflammation throughout the globe but no evidence of active 
organisms (Figure 7).
Figure 4 Loculated mass in superior anterior chamber with sclertitis.
Figure 3 stromal acanthamoebal cyst. PAs X 400.
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Discussion
The treatment of advanced Acanthamoeba sclerokeratitis 
is a challenge.1–3 It is diagnostically difficult to distinguish 
between secondary inflammatory reaction and actual 
acanthamoebal infection of the sclera.3 Topical treatment of 
the cornea may not achieve therapeutic levels in the sclera.12 
Systemic treatment with ketaconazole and fluconazole has 
been used in the treatment of Acanthamoeba keratitis and 
sclerokeratitis.12 Pentamidine has been shown to have effec-
tiveness against Acanthamoeba and has synergism with the 
biguanide compounds.4–10
The presence of chorioretinal inflammation in this eye 
does not necessarily indicate presence of Acanthamoeba in 
the posterior segment. Chorioretinal inflammation has been 
seen with the presence of Acanthamoeba13 and also as a 
sterile inflammation.14
The sudden development of intense ocular inflammation 
in this patient after apparent successful treatment of the 
infection led to the concern that active infection had 
recurred. The failure of a prolonged therapeutic response to 
intravenous pentamidine could indicate that the treatment 
was of insufficient duration, that therapeutic levels were not 
attained and/or maintained, or that the Acanthamoeba was 
resistant to pentamidine.
If the scleritis was an immune-mediated response,3 then 
aggressive systemic immunosuppression may have changed 
the course of this case. This was not used in this case because 
of the concern that the Acanthamoeba was active.
It is clear that the use of systemic pentamidine in this case 
did not effectively alter the progression of the disease and 
eventual loss of the eye. Perhaps earlier intervention or com-
bined systemic antiamebial therapy and immunosuppression 
would achieve a better outcome. Other systemic medications 
for the treatment of Acanthamoeba sclerokeratitis must be 
sought. Miltefosine and voriconazole have shown strong 
inhibitory effects on Acanthamoeba trophozoites in vitro 
and might be candidates for in vivo testing.15
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